MedTrace Logo

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

NCT04587479 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-01-13

No results posted yet for this study

Summary

This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.

Conditions

  • Solid Tumors, Adult

Interventions

DRUG

JAB-8263

Variable dose, orally Q2D with 28 days each cycle

Sponsors & Collaborators

  • Jacobio Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jacobio Pharmaceuticals · Jacobio Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2024-10-31
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04587479 on ClinicalTrials.gov